Josh Rosen and Jerry Derevyanny from Bengal Capital discuss the current state of cannabis investing (1:10). Trump takes action to reschedule cannabis; federal regulations and investment strategies (6:30). Challenges of valuation in the cannabis sector (19:00). Expected consolidation in the industry; insights for retail investors (23:20). Is there a first mover advantage? (26:30). Understanding 280E (30:00). Deep dive on Glass House (GLASF) (32:20). More on valuation (38:10). Public vs. private, hemp, ETFs (46:00).

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Cannabis expert Jesse Redmond shares why he's now at LEEF Brands (1:30). Excited about New York's evolution (8:15). How and why it got so bad in the industry (16:00). Are we early or are we wrong? (22:05) Who may survive and get to the finish line (28:35). Intoxicating hemp market (32:40).

Episode transcripts

Show Notes:
Cannabis REITs: Less Risky Choices In A Risky Sector
Green Thumb Stands Alone. Billions In Debt Coming For MSOs
Leef Brands

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Julian Lin updates his views on cannabis REITs IIPR and NewLake Capital (1:15). RIP Cannabis Growth Investor - changed thesis on cannabis MSOs (6:45). Why Green Thumb has done well relative to the sector (13:35).

Episode transcripts

Show Notes:
NewLake Capital: 9.3% Dividend Yield, No Net Debt, Rescheduling Catalyst
Marijuana rescheduling "delayed, but not dead": report
Best Of Breed Growth Stocks

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

High Tide is the largest cannabis retailer in Canada (1:20). President and CEO Raj Grover joins us to discuss its recent move into Germany (3:15). Purecan acquisition - a beautiful business to buy (8:00). Tilray is complementary, not competition (14:00). No hurry to get into the US (18:00). Contextualizing valuation and revisions (20:35).

Read episode transcripts

Show Notes:
High Tide outlines 2025 plans: 20-30 new stores and German market expansion
High Tide Q4 2024 Earnings Call Transcript
Cannabis In Germany - Legalize, Don't Decriminalize
High Tide website

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Why 2025 will be interesting and perhaps painful for the cannabis industry, according to Seth Yakatan (2:00). Enormous looming debt for many companies (5:15). GTI the only company consistently delivering year-in and year-out (8:30). TerrAscend, Ascend and the 2nd tier of MSOs (12:00). Glass House seemingly winning its bet on scalability (19:15). Which private companies have some of the best assets in the industry (28:10). MSOS, MSOX and cannabis ETFs (35:25).

Read episode transcripts

Show Notes:
Tremendous Opportunity In Cannabis
Green Thumb Industries Virtual Analyst Report

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

CannaVestments and Jerry Derevyanny return for an in-depth episode. Dissecting doom and gloom Q3 earnings for the cannabis industry (0:50). Green Thumb's consistently outstanding performance (4:25). Is it too early or too late to invest in cannabis? (11:15) Florida not legalizing - how much does it matter? (17:30) Agrify's interesting moves (35:40). Hemp, beverages and what may be worthy of investors' attention (40:00). Glass House discussion (47:40). Shorting Curaleaf? (53:55)

Read episode transcript

Show Notes:
Bengal Capital - Grown Rogue: Remains Materially Undervalued, Best Days Still Ahead
Cannabis Investors - What You Should Know
How Retail Investors Should Evaluate Cannabis Stocks
Tremendous Opportunity In Cannabis

Black Friday Sale: 20% Off Seeking Alpha. Find the right investment tools to reach your goals! 

Grown Rogue has been lauded by a number of analysts on this show so we decided to talk to VP Jake Iotte about what makes the company stand out and whether cannabis belongs in the CPG industry (1:30). Margins and ROI profile; focused on cash on cash returns (4:20). Excited about Jersey (7:10). Terminating partnership with Vireo (8:25). Not relying on federal legalization as a strategy (10:50).

Read episode transcripts

Show Notes:
Bengal Capital - Grown Rogue: Remains Materially Undervalued, Best Days Still Ahead
Cannabis Investors - What You Should Know
Grown Rogue: Poised For Explosive Growth

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Jesse Redmond highlights the fine line between being early and wrong and why having a long-term timeline is wise for cannabis investors (2:10). Why Florida is a massive opportunity (9:35). Green Thumb, Verano and pushing for more company transparency (17:50). Pennsylvania a state-led catalyst; solving for the current risks to getting into cannabis (26:05). Farm Bill flower, the hemp conversation, valid excitement over Ohio and Minnesota and Glass House (31:20). Top 3 ways to allocate capital for retail cannabis investors (52:00).

Read episode transcripts

Show Notes:
Trump appears open to decriminalizing marijuana
Ayr CEO David Goubert On Florida, Ohio And 'Very Balanced' Q2
Texas Cannabis, Delta-8 And Delta-9
Glass House's Graham Farrar On Industry Challenges And Opportunities

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Ayr Wellness CEO David Goubert talks 'very balanced' Q2 earnings. (1:15) Focus on state footprints: Florida legalization, Ohio's nice rollout. (6:00) Debt and dilution: progress and strategies. (8:15) Any plans to grow hemp? (21:15) Industry valuations as the market evolves and legalization develops. (23:00) How to establish a national brand and the general cannabis retail picture. (36:00)

Read episode transcripts

Show Notes:
Ayr Wellness CEO David Goubert Focused On Debt And Cash
Cannabis stocks on watch as DEA sets hearing on marijuana rescheduling
Ayr Wellness Q2 2024 Earnings Call Transcript
Florida MSO Trump Card

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD and Lykos Therapeutics (1:35). Blessing in disguise for Cybin, COMPASS Pathways and MindMed (14:30)? Trial data and cash in the bank are top signifiers of success (22:35). How Atai fell behind and dropped out of the conversation (24:00). Upcoming catalysts - patience required (26:35). For psychedelic medicine, does it matter who's in the White House (29:30)?

Read episode transcripts

Show Notes:
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
ATAI: Enormous Potential Upside But No Clarity Yet
De-Risking Psychedelics: Compass Pathways, Cybin And Atai

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

On June 18 at our Seeking Alpha Investing Summit, Pablo Zuanic, Tim Seymour, and Julian Lin discussed how to best invest in the sector (0:20). Best metrics to use when evaluating cannabis stocks (4:40). At this point in time, what is the best way to get into the sector? (19:00) Rescheduling, the Trump factor, investing in an election year (26:40). Originally published here with video.

Cannabis Growth Portfolio

Show Notes:
NewLake Capital, IIPR And Cannabis REITs
Cannabis ETF Deep Dive
A New Age For Crypto
Marijuana rescheduling proposed rule comments due by July 22

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades, become a Premium subscriber: seekingalpha.com/subscriptions

Jerry Derevyanny and Julian Lin break down the current state of the cannabis sector (1:00). How companies are massaging their earnings results (3:30). Proper metrics to use as the market develops (7:45). Green Thumb's growth mode and solid margins (16:05). Institutional capital and what will really make the industry soar (21:15). Thoughts on Verano and Goodness Growth (47:25). New states coming online - worthy of excitement? (57:35) NewLake Capital, cannabis REITs and dividend yields (1:08:40).

Show Notes:
How Retail Investors Should Evaluate Cannabis Stocks
What Has Verano So Optimistic About The Cannabis Industry?
MasterClass In Cannabis Investing Redux
My Top Pick: NewLake Capital Yields 12% With Net Cash Balance Sheet And Built-In Growth

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades:  seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (with your podcast discount code!)

Alex Carchidi talks why he's bullish on the cannabis sector, but not ready to buy stocks (1:15) except for IIPR (2:15). 2 cannabis stocks worth looking at (7:25). Tilray the only international option (13:30). Who looks good in Canada (16:40). Why Alex avoids MSOS ETF (22:30). Legalization, rescheduling and incremental change (23:20).

Show Notes:
Biden administration reportedly moves to reclassify marijuanaTrulieve Cannabis: Up Over 122% In 2024, But Where Does It Go Next?
What Cannabis Reform In Germany Means For North American Marijuana Companies
Canopy Growth Is Climbing, But It Won't Last

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (don't forget your podcast discount code!)

Verano (VRNOF) CEO George Archos and CIO Aaron Miles on recent earnings and why they're the most optimistic they've been (0:45). Company transparency like state by state data (7:50) and what metrics they're each focused on (12:05). Why they're so excited about Florida, Ohio and Pennsylvania (14:35). The federal regulation roller coaster (21:05).

Show Notes:
How Retail Investors Should Evaluate Cannabis Stocks
Cannabis Investors - What You Should Know
Verano Holdings Q1 2024 Earnings Call Transcript
White House mum on where Biden stands with marijuana rescheduling

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (don't forget your podcast discount code!)

Mario Naric, CEO and Founder of Motif Labs, discusses being in the shakeout phase of cannabis in Canada (1:00). Staying private while public companies suffer (5:25). How to grow market share in Canada (12:53). Near-term reality for big Canadian LPs like Tilray and Canopy Growth (18:00). Different products for different markets within US and Canada (23:20). Where should investors allocate their capital in this space? (40:40)

Show Notes:
Oh No, Canada
Cannabis Investing With Alan Brochstein & Julian Lin - REITs And Canadian LPs Over MSOs
DEA to reschedule marijuana as a less dangerous drug: AP

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Motif Labs

David Hart recently became CEO of The Cannabist Company and is focused on building a strong asset base in the US cannabis market (1:35). Metrics and internal expectations, wholesale business; finding ways to improve margin profile and cash generation (11:25). Is more transparency coming?(14:45) Thoughtful ways of approaching debt (17:10). Industry rallies, price drops and technical overhangs (26:40).

Show Notes:
Cresco Labs, Columbia Care call off merger
How Retail Investors Should Evaluate Cannabis Stocks
The Cannabist Company enters into debt repurchase agreement
Seeking Alpha’s Quant Rating on Cannabist

Episode transcripts

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Bengal Capital's Jerry Derevyanny shares his evolving thoughts on 280E and the process of rescheduling cannabis (2:20). Some uncomfortable truths about how investors should be evaluating cannabis stocks (8:30). When will companies become more transparent? (21:40) Who is handling debt well and who isn't (27:15). Examples of sustainable value creation in the industry (34:00).

Episode transcripts

Show Notes:
Bengal Capital FY2023 Letter
Where Is The Value In Cannabis Stocks?

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Katie Neer and Hirsh Jain break down the dispiriting New York and California cannabis markets (3:00). What the 2 states have gotten wrong, and why it's not being corrected (9:55). Dysfunction and pushing regulators and the law to work better (34:45). Are there investment opportunities in either market? (47:40)

Episode transcripts

Show Notes:
Unpacking New York And California Cannabis Markets
What's The Deal With New York Cannabis?
California Cannabis Market - Deep Dive, Part II

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter
Katie Neer
Hirsh Jain

Alan Brochstein thinks investors are overly excited about the recent rescheduling announcement, which he says is really no news at all (2:20) Balance sheets, debt, income tax payable and the burden of 280E (4:00) California and New York continuing challenges (23:20) What's right and wrong with Canada (32:30) Broad and specific thoughts on MSOs (38:10).

Subscribe to Alan's 420 Investor

Episode transcripts

Show Notes:
Beaten-Up Planet 13 Is A Solid Cannabis Investment
Trulieve Is Cheap But Perhaps Risky
Curaleaf Is A Bad Cannabis Investment
Why Organigram Is My Favorite Cannabis Stock
Cannabis Investing With Alan Brochstein & Julian Lin - REITs And Canadian LPs Over MSOs

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter

Alex Carchidi updates us on the psychedelic sector and what critical catalysts are approaching (1:30). Why Compass Pathways, Cybin, and Atai make the most sense for investors at this point (15:00). Pros and cons of 4 main industry stocks, including MindMed (29:50).

Episode transcripts

Show Notes:
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Psychedelic Stocks: Don't Bet On Just 1 Company
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
Cybin: A Leading Early-Stage Psychedelics Play

For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions

Cannabis Investing Podcast on Twitter